Kelly Valla, PharmD, BCOP, On Common Adverse Effects Associated With Tazemetostat
Adverse effects in patients taking tazemetostat were manageable, with most patients reporting low-grade fatigue, pain, and nausea.
For the latest installment of the “Product Profile”, ONCOLOGY® spoke with Kelly Valla, PharmD, BCOP, about tazemetostat (Tazverik) as therapy for patients with follicular lymphoma. Here, she discusses some toxicities that were associated with therapy, stating that not many adverse effects of grade 3 or 4 severity were reported.
Transcription:
In the clinical trial that garnered its approval by the FDA, tazemetostat was really well tolerated. Most toxicities were low-grade to grade 1/2—things like nausea and abdominal pain, [along with] some upper respiratory tract infections and other gastrointestinal disturbances. Overall, there were low rates of grade 3/4 toxicities, so this is a well-tolerated agent. [However, because] this agent was [just] approved, less than a year ago, we still have a lot of information to gather about what some of its long-term toxicities may be.
Reference:
Tazverik. Prescribing information. Epizyme; 2020. Accessed May 21, 2021. https://bit.ly/3oBelE6
Between the Lines Podcast: Tazemetostat in Relapsed/Refractory Follicular Lymphoma
November 3rd 2022Expert oncologist/hematologists Bruce Cheson, MD, FACP, and Steven Park, MD, discuss findings from the E7438-G000-101 trial and consider the efficacy of tazemetostat as treatment for relapsed or refractory follicular lymphoma.
